DOT-HDC-Header

Histone deacetylases (HDACs) have proven to be a promising target for drug intervention and there are a number of HDAC inhibitors (HDACi) currently being tested in pre-clinical and clinical stages. HDACi were primarily developed as anti-tumor agents for cancer, but many are now being explored for treating neurodegenerative, immunologic, metabolic, inflammatory and cardiovascular disorders. However, much remains to be elucidated about the functional implications of modulating HDACs and understanding the signaling pathways that can cause adverse cellular effects and unwanted toxicity. Next Generation Histone Deacetylase Inhibitors, tracks both the scientific and clinical progress being made to better understand the cellular function of this complex drug target family.

Preliminary Agenda

KEYNOTE:
Low Dosing of HDAC Inhibitors for Treating Inflammatory Diseases

Charles Dinarello, M.D., Professor of Medicine and Immunology, University of Colorado School of Medicine, and Professor of Experimental Medicine at Radboud University, Netherlands

FEATURED PRESENTATION:
Role of Selective HDAC6 Inhibitors in Cancer Immunotherapy

Eduardo Sotomayor, M.D., Susan and John Sykes Endowed Chair in Hematologic Malignancies, Scientific Director, DeBartolo Family Personalized Medicine Institute, and Professor of Oncologic Sciences, Pathology and Cell Biology, University of South Florida College of Medicine


PROBING NEW HDAC CHEMISTRIES & FUNCTION

Hydroxamates Versus Non-Hydroxamates: Charting a Path to HDAC6 Inhibitors That Are Not Ames Positive

Alan P. Kozikowski, Ph.D., Professor, College of Pharmacy Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago

Defining the HDAC Independent Effects of Hydroxamate-Based Inhibitors in Neuroprotection

Edward Holson, Ph.D., Director, Medicinal Chemistry, Stanley Center for Psychiatric Research and Director of Chemistry, Chemical Biology Platform, Broad Institute

Imaging HDAC Density and Drug Inhibition in the Human Brain

Jacob Hooker, Ph.D., Assistant Professor, Radiology, Harvard Medical School


UNDERSTANDING CELLULAR CROSS-TALK

Similarities and Differences Between the Effects of Isoform-Selective HDAC Inhibition and HDAC Gene Deletion

Wayne W. Hancock, M.D., Ph.D., Professor of Pathology and Chief of Transplant Immunology, Children's Hospital of Philadelphia and University of Pennsylvania

HDAC Inhibitors for Cardiovascular Disease

Timothy A. McKinsey, Ph.D., Associate Professor and Associate Division Head for Translational Research, Department of Medicine, Division of Cardiology, University of Colorado Denver


EXPLORING BIOLOGY FOR EFFECTIVE THERAPIES

Talk Title to be Announced

Stephen Shuttleworth, Ph.D., Chief Scientific Officer, Karus Therapeutics Ltd.



For more details on the conference, please contact:
Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute
E: tkoppal@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

DOT Hub Icon

2014 Discovery on Target Brochure  


IPR_Micrombiome 


2014 BROCHURE 

 PREMIER SPONSORS 

Cellecta 

Molecular Sensing 

Rosa Drug Development Advisors
 

VIEW ALL SPONSORS 

VIEW MEDIA PARTNERS 


SPONSORSHIPS & EXHIBITS 

The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com 


Westin Boston Waterfront

HOTEL & TRAVEL 

Westin Boston Waterfront
425 Summer Street
Boston, MA 02210
617.426.2000